Tyra Biosciences, a preclinical biotech developing FGFR kinase inhibitors for solid tumors, raised $173 million by offering 10.8 million shares at $16, the high end of the range of $14 to $16. The company offered 1.8 million more shares than anticipated. It...read more
Tyra Biosciences, a preclinical biotech developing FGFR kinase inhibitors for solid tumors, raised the proposed deal size for its upcoming IPO on Tuesday.The Carlsbad, CA-based company now plans to raise $135 million by offering 9 million shares at a price...read more
Updated Monday, 9/13.After a wave of launches in the short holiday week, 11 IPOs are scheduled to raise over $3 billion in the week ahead.Tech consultancy Thoughtworks (TWKS) plans to raise $700 million at a $6.3 billion market cap. This agile software...read more
US IPO Weekly Recap: The Fall IPO market is in full swing with an 11 IPO week
...read more
Oncology biotech Tyra Biosciences prices further upsized IPO at $16 high end
Tyra Biosciences, a preclinical biotech developing FGFR kinase inhibitors for solid tumors, raised $173 million by offering 10.8 million shares at $16, the high end of the range of $14 to $16. The company offered 1.8 million more shares than anticipated. It...read more
Oncology biotech Tyra Biosciences ups share offering by 34% ahead of $135 million IPO
Tyra Biosciences, a preclinical biotech developing FGFR kinase inhibitors for solid tumors, raised the proposed deal size for its upcoming IPO on Tuesday.The Carlsbad, CA-based company now plans to raise $135 million by offering 9 million shares at a price...read more
US IPO Week Ahead: The Fall IPO market kicks off with an 11 IPO week
Updated Monday, 9/13.After a wave of launches in the short holiday week, 11 IPOs are scheduled to raise over $3 billion in the week ahead.Tech consultancy Thoughtworks (TWKS) plans to raise $700 million at a $6.3 billion market cap. This agile software...read more